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Disruption of Microtubules Post-Virus Entry
Enhances Adeno-Associated Virus Vector Transduction
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Perinuclear retention of viral particles is a poorly understood phenomenon observed during many virus
infections. In this study, we investigated whether perinuclear accumulation acts as a barrier to limit
recombinant adeno-associated virus (rAAV) transduction. After nocodazole treatment to disrupt micro-
tubules at microtubule-organization center (MT-MTOC) after virus entry, we observed higher rAAV
transduction. To elucidate the role of MT-MTOC in rAAV infection and study its underlying mechanisms,
we demonstrated that rAAV’s perinuclear localization was retained by MT-MTOC with fluorescent
analysis, and enhanced rAAV transduction from MT-MTOC disruption was dependent on the rAAV
capsid’s nuclear import signals. Interestingly, after knocking down RhoA or inhibiting its downstream
effectors (ROCK and Actin), MT-MTOC disruption failed to increase rAAV transduction or nuclear entry.
These data suggest that enhancement of rAAV transduction is the result of increased trafficking to the
nucleus via the RhoA-ROCK-Actin pathway. Ten-fold higher rAAV transduction was also observed by
disrupting MT-MTOC in brain, liver, and tumor in vivo. In summary, this study indicates that virus
perinuclear accumulation at MT-MTOC is a barrier-limiting parameter for effective rAAV transduction
and defines a novel defense mechanism by which host cells restrain viral invasion.
INTRODUCTION
CELLS HAVE MANY STRUCTURES and machineries to
protect themselves from exogenous infectious agents
(e.g., viruses and bacteria).1 For example, beside
the extracellular matrix and a number of extra-
cellular factors that can restrict infections, the
plasma membrane is an important structure to
limit viral infection, whereas molecularly dense
cytoplasm and the nuclear envelope serve as ad-
ditional barriers for viruses to reach their repli-
cation sites. As a consequence, viruses have to
overcome these cellular barriers in host cells be-
fore delivering their genome to the target region
for successful infection. Comprehensive knowledge
about these barriers and virus–host interactions
is critical in improving our understanding of basic
virology and viral pathogenesis. Both strength-
ening these cellular barriers and weakening the
viral capacity to penetrate these barriers present
potentially powerful means for inhibition of viral
infection. On the other hand, attenuating these
barriers or designing capsid with enhanced ability
to penetrate these barriers will offer promising
opportunities to improve current vectors for gene
therapy.
The microtubule-organization center (MTOC) is
a subcellular structure at perinuclear region, from
which microtubules (MTs) are nucleated to form a
radial filamentous network with minus ends an-
chored at MTOC and plus end reaching cell surface
area.2 Because of these features, MTs and MTOC,
as a trafficking center, coordinate the transport
of intracellular molecules and organelles between
the perinuclear region and other areas of a cell.2
For instance, intact MTs are required for the nu-
clear import of several transcription factors (e.g.,
p53, NF-kB, pRb), and on other hand, these struc-
tures are required to sequester other proteins (e.g.,
c-myc, MIZ-1, smad3) in the cytoplasm to block
their nuclear entry.3–7 Numerous studies have also
shown that cellular misfolded proteins are trans-
ported on MTs toward the MTOC region, where
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these misfolded proteins are then sequestered or
degraded by proteasomes and lysosomes.8,9
Strikingly, during the early stage of infection,
many incoming viruses are also delivered to and
retained at a perinuclear site after entering the
cells.10–16 It has been suggested that this peri-
nuclear site is co-localized with the MTOC region
and, as observed for cellular proteins, that trans-
port of these viruses along with MTs is facilitated
by dynein motors.9,17 Although this perinuclear
retention of incoming virions seems to be a common
phenomenon among many viruses, especially those
that enter the nucleus, it remains unknown whe-
ther this accumulation is beneficial or inhibitory to
viral infection.9 Previous studies have shown that
several viruses, including rotavirus, vaccine, and
HSV, disrupt MTOC during early infection stage
for reasons that have not been identified.18–22 De-
spite the lack of understanding of the role of such
perinuclear retention on viral infection, these ob-
servations raise an intriguing hypothesis that
MTOC region serves as a subcellular barrier to
restrict access of the incoming virions to their
replication site (nucleus in this study) during the
early stage of viral infection.
On the other hand, during late infection stage,
several viruses, such as HIV, HSV, poliovirus, and
norovirus, have been suggested to exploit this
perinuclear accumulation to concentrate newly
synthesized viral components through MTs in
order to facilitate late infection events, including
virion replication, assembly, or egress.23–26 Classical
virology assays usually study replication-competent
viruses and measure the production of viral prog-
eny as the readout, which is the sum of the total
effects of all events in viral infection with these
viruses. Given the potential involvement of MTs
and MTOC throughout the entire viral infection,
this method is unable to precisely dissect the
perinuclear retention of incoming virions during
early infection stage. Furthermore, viral replica-
tion and newly synthesized viral proteins will
also confound virion distribution assays that use
antibodies.12,15
Recombinant viruses used as gene therapy vec-
tors (designated as viral vectors) are purposely
designed to exploit only the early infection steps,
including delivering and expressing viral genomes,
and are deficient in late infection events, including
viral replication and assembly because of the de-
letion of critical viral proteins.27 As a result, these
viral vectors allow researchers to more precisely
separate the early infection steps from the late
events, offering a promising opportunity to specif-
ically identify the mechanisms and roles of peri-
nuclear retention on incoming virions. Adeno-
associated virus (AAV) is a member in the family
Parvoviridae and recombinant AAV (rAAV) is
currently used as a gene therapy vector because of
many desirable traits in gene delivery.27 As a gene
therapy vector, rAAV does not contain any viral
DNA except for two inverted terminal repeats
(ITR) flanking the exogenous transgene.27 There-
fore, rAAV only delivers and expresses transgenes
in cells but is incapable of replicating and produc-
ing viral progeny. This attribute makes rAAV a
useful model to specifically investigate virus–host
interplay during the early stage of viral infection.
Like many other viruses, its trafficking pathway
typically starts with receptor-mediated endocyto-
sis for cell entry, followed by cytoplasmic traffick-
ing assisted by the endosomal routing system and
MT network, and ends with nuclear entry and
uncoating for successful transduction.27–29
In our previous study, using pharmacological
agents, live-cell imaging, and flow cytometry anal-
ysis, we have demonstrated that rAAV2 exploits
MTs for rapid cytoplasmic trafficking in endosomal
compartments unidirectionally toward the peri-
nuclear region and that rAAV2 transduction is re-
duced when the MT network is disrupted at early
time point of rAAV infection.30 In this study, we
investigated the role of rAAV perinuclear retention
on the effective transduction, and have further
explored the detailed mechanism. A sensitive and
reliable fluorescence imaging platform allowed us
to examine viral trafficking in detail over time,
which led us to the observation that the majority of
viral particles finish cytoplasmic trafficking and
localize at perinuclear region by 6–8 hr postinfec-
tion (p.i.). Manipulating host cells and viral parti-
cles using pharmacological interventions around
6–8 hr p.i. allowed us to efficiently investigate the
underlying mechanism of perinuclear retention as
well as the corresponding impact on viral infection.
MATERIALS AND METHODS
rAAV2 production, purification, and labeling
HEK-293 cells were used to produce rAAV2 as
described previously.31 Briefly, cells were trans-
fected with three plasmids: pXR2 (wt or with BR
mutations), pXX680, and a plasmid containing the
reporter transgene (GFP or Luciferase) flanked by
two ITRs. At 60 hr after transfection, cells were
collected and nuclei were isolated using hypotonic
buffer and Kontes homogenizer. rAAV2 particles
were recovered by resuspending the nuclear pellet
in PBS with 0.5% deoxycholate (DOC) and then
sonicating for 1 min. Highly pure virus was then
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retrieved as described previously.32 Briefly, after
DNase treatment, the virus suspension was sub-
jected to one round of cesium chloride (CsCl) step
gradient density fractionation and another round
of fractionation using a continuous CsCl gradient.
Determination of peak viral fractions, dialysis of
virus, and measurement of viral titers by quanti-
tative PCR (qPCR) were performed as previously
described. The infectivity of AAV was determined
to be approximately 1 transducing unit per 100
particles.
rAAV2 was covalently labeled with the Cy5
fluorophores as described in manufacturer’s proto-
col with slight modification. Briefly, purified rAAV2
were incubated for 2 hr at 4C in PBS with a 20-fold
molar excess of Mono-NHS-Cy5 (GE Healthcare)
over capsid protein units. Free dyes were removed
from labeled viral particles by dialysis against PBS
containing 5% sorbitol and viral solutions were
stored at -80C as small aliquots. Labeled viral ti-
ters were determined by both dot blot31 and qPCR.
Infectivity of the viral particles was determined by
GFP reporter gene assay.
Cell culture, viral infection, and drug treatment
All cells (American Type Culture Collection)
were grown in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen) with 10% FBS in 5% CO2 in-
cubator. Cells were passaged every 2–3 days for up
to 10 passages, when new aliquots of frozen cells
were recovered from liquid nitrogen.
For pulse infection, cells were seeded on 12 mm
glass coverslips at 24 hr before infection. The next
day, after incubation in DMEM containing 20 mM
HEPES at 4C for 5 min, cells were inoculated with
Cy5-rAAV2 (*5,000 vgs/cell) or nonlabeled rAAV2
(*1,000–5,000 vgs/cell) at 4C for another 40 min.
Cells were then washed with PBS to remove un-
bound virions and transferred to a 37C incubator
(regarded as 0 hr p.i.). Pharmacological drugs were
added at 6–8 hr after pulse infection unless other-
wise indicated. The concentrations of drugs were
30lM nocodazole, 25lM colchcine, 10lM taxol,
10lM rhizoxin, 10lM maytansine, 2 lM MG132,
20lM ALLN, 10lM H1152, and 10 lM cytochala-
sin D. The drugs were maintained in the culture for
approximately 3 hr unless otherwise indicated.
Flow cytometry and immunofluorescence
To evaluate viral transduction, flow cytometry
analysis was used to measure the mean fluores-
cence intensity (MFI) of GFP expression. Since
slight cell toxicities from the drug treatment were
observed (data not shown), to exclude the potential
effect of dead cells on the viral transduction mea-
surement, we washed the cells in each well three
times with PBS before harvesting for flow cytom-
etry analysis, removing any floating or loosely at-
tached cells. Either Trypan blue exclusion or 7-
AAD exclusion assays was used to ensure cell via-
bility over 95% for flow cytometry analysis.
For immunofluorescence, cells were washed
with PBS and then fixed with 4% paraformalde-
hyde (PFA) for 15 min at room temperature (RT).
The cells were then permeabilized with 0.2% Triton
X-100 in PBS for 5 min at RT. After blocking with
immunofluorescence buffer (IFB) (5% normal goat
serum in PBS containing 0.05% Tween-20) for 1 hr
at RT, the cells were incubated with primary an-
tibody to detect tubulin (Ab6161; rat monoclonal
from Abcam Inc.), Golgi (Ab24586; mouse mono-
clonal from Abcam Inc.), and/or rAAV capsid (A20
mouse monoclonal antibody) diluted in 50%
IFB overnight at 4C. The cells were then incubated
with secondary antibody, diluted 1:2,000 in 50% IFB
(antimouse Alexa-Fluor 488; Molecular Probes) for
1 hr at RT. After six washes with PBS, coverslips
were mounted cell side down on glass slides with
mounting medium (prolong antifade gold with DAPI
[4¢,6¢-diamidino-2-phenylindole]; Molecular Probes).
After images were acquired using confocal micros-
copy, the existence of perinuclear accumulation in a
cell in each image was examined by human eyes.
Nuclear isolation and viral genome quantification
Nuclei were isolated from cell fractionations
as previously described,31 with minor modifications
allowing for viral infection. After incubation with
rAAV and drugs, cells were washed three times with
ice-cold PBS and harvested by centrifugation at 500
g for 10 min. The cell pellet was divided into two
aliquots: one for direct viral genome extraction and
the other for nuclei isolation. One aliquot was re-
suspended in hypotonic buffer and homogenized on
ice using a Kontes homogenizer to the point where
*90% of cells were broken with nuclei remaining
intact. The homogenate was spun at 500 g for 10 min
to separate the nuclei from the cytoplasmic compo-
nents. The purity of nuclear fraction was assured by
phase-contrast microscopy and immunoblotting
using antitubulin and antilamin A/C antibodies,33
and no cytoplasmic protein tubulin was detected in
purified nucleus (data not shown).
rAAV genomes were recovered from both whole
cells and nuclear fraction using DNeasy Blood
and Tissue Kit (Qiagen Inc.) according to the
manufacturer’s protocol. The copy number of rAAV
genomes was determined by qPCR on a Light-
Cycler 480 using SYBR Green (Roche) as described
for viral titering.31
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Animal studies
Housing and handling of the BALB/c mice and
SCID mice used in the current study were carried
out in compliance with National Institutes of
Health guidelines and approved by the IACUC at
the University of North Carolina–Chapel Hill. To
grow xenografted breast cancer tumors, 106–107
MDA-231 breast cancer cells were injected into the
mammary fat pad of SCID mice. When the tumor
size was about 0.5 cm in diameter, the mice were
used for intratumoral injection. Recombinant AAV2
vectors packaging luciferase or GFP transgenes
were administered through the intravenous route
(2·1010 vgs into tail vein) in a volume of 200ll PBS
or the intratumoral route (1·1010 vgs). DMSO or
nocodazole (2 mg/kg) were administered via intra-
peritoneal or intratumoral injection at about 10–
12 hr after viral injection. Bioluminescence from
luciferase expression was visualized by using a
Xenogen IVIS100 imaging system (Caliper Life-
sciences) after intraperitoneal injection of luciferin
substrate (120 mg/kg of body weight; Nanolight).
Image acquisition and analysis were carried out
using Living Image software. Quantitative data are
based on values from 3 to 4 mice per group.
For vector infusions into mouse brain, animals
were anesthetized with isoflurane and placed into a
stereotaxic frame. Using a 32-gauge stainless steel
injector and a Fisher Scientific infusion pump, mice
received 1ll per hemisphere (total of 5· 108 vgs)
into the striatum over 15 min. The injector was left
in place for 3 min after infusion to allow diffusion
from the site of injection.
To image viral trafficking in mouse tissues,
Cy5-rAAV2 was administrated through intrabrain,
intrahepatic, or intratumoral routes. DMSO or
nocodazole were administrated through the intra-
peritoneal route at about 12 hr after viral inocula-
tion. At 1 or 12 hr after vector injection or 4–6 hr
after nocodazole injection (16–18 hr after viral in-
jection), animals received an overdose of pento-
barbital (100 mg/kg intraperitoneally) and were
perfused transcardially with ice-cold 100 mM so-
dium PBS (pH 7.4), followed by 4% PFA in phos-
phate buffer (PB) (pH 7.4). After tissues were
postfixed for 24 hr at 4C in PFA,34 10–20lm cor-
onal sections were cut using a cyrosection micro-
tome and then the slides were directly sealed with
mounting medium (Prolong Antifade Gold with
DAPI [4¢,6¢- diamidino-2-phenylindole]; Molecular
Probes).
Quantitative 3D microscopy
Hela cells pulse infected with Cy5-rAAV2 were
fixed with PFA and mounted to glass slides as de-
scribed above. The distribution of viral particles in
Hela cells was examined using a Zeiss LSM710
laser scanning confocal microscope equipped with a
Plan-Apochromat 63·/NA 1.40 oil objective. Stacks
of 20–30 focal planes were captured at 0.31 lm
z-intervals through the depth of the cell. 3D images
of the cells were reconstructed using the Z-stacks.
All images were acquired at pixel dimensions of
0.13 lm · 0.13 lm · 0.31lm (X, Y, Z) to fulfill the
Nyquist sampling.
Deconvolution was performed by the Auto-
Deblur software (Media Cybernetics Inc.) using
iterative and constrained algorithms as described
previously.32 The procedure started with a theo-
retical PSF derived from the actual settings of
Zeiss710 confocal microscope, including NA of the
microscope objective, refractive index of the me-
dium, excitation wavelength, emission wavelength,
confocal pinhole radius, pixel size, z-axis interval,
and microscope type (i.e., wide field, confocal). A
new adjusted adaptive PSF derived from the pre-
vious deconvolution round was used to generate the
next adaptive PSF that fit the real imaging data
better than the previous one (termed as one itera-
tion or deconvolution round). Twelve rounds of it-
eration were used to deconvolve all the confocal
images in this study.
All deconvolved image stacks were processed
using the IMARIS software package (Bitplane
AG, Zurich, Switzerland) for visualization and
quantification as described previously.32 Briefly,
each deconvolved image stack was reconstructed
using a volume-rendering module and smoothed by
a 3D-median filter. Subsequently, an isosurface-
rendering module was applied through threshold-
ing by the fluorescence intensity that was slightly
higher than background. For Cy5-rAAV2, the iso-
surface rendering was thresholded at the fluores-
cence intensity of 2000 a.u. (the upper boundary
of background). For DAPI, isosurface rendering
was thresholded at the fluorescence intensity
of 3200 a.u.. Parameters (volume, MFI, TFI) for
these isosurface-coated Cy5-rAAV2 objects were
extracted from the IMARIS program and analyzed
to determine the localization of particles as de-
scribed previously.32
Negative staining and electron microscopy
Purified and dialyzed virus particles in 1· PBS
were pipetted onto a glow-discharged copper grid.
The grid was washed twice with water and then
stained with 2% uranyl acetate. Electron micros-
copy images were taken with a LEO EM 910
transmission electron microscope at various mag-
nifications.
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Transient transfection of reporter
plasmid and siRNA
For transfection of Hela cells with reporter plas-
mids, Hela cells were plated at a density of 4·105
cells/well and 24 hr later were transfected with TR-
CMV-EGFP reporter plasmids using PEI. For each
well, 500 ng DNA was mixed with 5ll PEI (1 mg/ml)
in 100ll of serum-free DMEM and incubated at RT
for 10 min before addition to cell medium. Culture
medium was refreshed at 6 hr after transfection. At
16–20 hr after transfection, cells were treated with
DMSO or other drugs as indicated. At about 20 hr
after drug treatments, cells were harvested for flow
cytometry analysis of GFP expression as indicated
above. The control is the data without any treat-
ment after transfection. The effect of treatments on
transgene expression was calculated as 1· data of
treatment/positive control.
Knockdown of RhoA was obtained by double
transfection of siRNA (Dharmacom, Thermo Scien-
tific) using Nucleofector (Lonza Inc.) performed with
an Amaxa Electroporator according to the manu-
facturer’s protocol. Knockdown efficiency was veri-
fied by Western blot using RhoA antibody (Abcam
Inc.). Efficient knockdown was achieved two days
after the first siRNA transfection. After verifying
knockdown, approximately two days posttransfec-
tion, cells were processed with pulse infection and
drug treatments as described above. Viral trans-
duction was analyzed using flow cytometry.
Statistical analysis
Experiments were performed in triplicates and
repeated at least three times independently, un-
less otherwise noted. For studies comparing quan-
tification of luciferase or GFP expression in one
treatment group to the corresponding control group,
the Student t-test of the mean expression value was
performed. For studies comparing quantification
of luciferase or GFP expression in more than two
treatment groups to the same control group, the
one-way analysis of variance (ANOVA) was per-
formed to test the global hypothesis that all mean
values are the same across groups. If the global
hypothesis is rejected, Dunnett’s test was used to
compare the mean of each treatment to the mean of
control group simultaneously. Luciferase or GFP
expression was presented as mean–SD, and all
tests were considered significant if p<0.01, which
was indicated by *.
RESULTS
AAV retention in MOTC
AAV is a nonenveloped single-stranded virus
and has successfully been used as gene delivery
vehicle in clinical trials. To elucidate the role of
MTOC in rAAV transduction, we first investigated
the intracellular trafficking of rAAV2 over time
using viral particles labeled with Cy5. With our
optimized protocol, we were able to visualize a
single viral particle, and the labeled virions re-
mained as infectious as unlabeled particles.32
Specifically, homogeneous labeling of virions was
achieved by confocal microscopy of labeled particles
on glass coverslips (Supplementary Fig. S1A, left;
Supplementary Data are available online at
www.liebertpub.com/hum). The intensity profile of
fluorescent spot followed a single Gaussian distri-
bution, suggesting that the fluorescence signal was
from a single particle (Supplementary Fig. S1A,
right).35 The signal had a diameter of about 0.4lm
as determined by Full Width at Half Maximum
(FWHM), consistent with the fluorescent signal
from other nano-sized viruses.35 Data from negative
staining and electron microscopy demonstrated that
the virion structure remained unchanged and that
most of the labeled virions were single particles
(Supplementary Fig. S1B). To test whether labeling
would affect the functionality of the virions, we
compared labeled and unlabeled AAV particles in
their ability to transduce cells using GFP reporter
gene assay. We found that the labeled virions can
express GFP transgene as efficiently as the unla-
beled ones, indicating that the particles labeled with
Cy5 were fully competent at transduction (Supple-
mentary Fig. S1C). It has been relatively difficult to
visualize virions on the cell surface presumably be-
cause most virions were bound as single particle and
the visualization method was not sensitive enough
to detect them at single particle level.33 In contrast,
we were able to visualize the AAV particles on the
cell surface after 40 minutes of incubation of cells
with Cy5-rAAV at 4C (Supplementary Fig. S1D,
left). In addition, the Cy5 fluorescent signal was
successfully co-stained with the signal from mono-
clonal A20 antibody that specifically recognizes the
intact rAAV2 capsids (Supplementary Fig. S1D,
right). These data demonstrate that our labeling
and imaging systems are sufficiently robust and
reliable to study the viral trafficking and infection at
the level of a single particle.
To study the intracellular trafficking of rAAV,
we synchronized particle trafficking using ‘‘pulse
infection,’’ in which cells are incubated with virions
at 4C for 40 min and unbound virions are then
washed away before cells are transferred to 37C
for subsequent viral infection. After pulse infec-
tion, we studied the distribution of rAAV particles
at several time points over 12 hr (Fig. 1A). During
the first 2–4 hr p.i., the majority of viral particles
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were scattered in the cytoplasm and trafficking
toward the perinuclear region. At 4 hr p.i., the
majority of viral particles had finished their cyto-
plasmic trafficking and localized at the perinuclear
region in approximately 30–40% of cells. At 8 hr
p.i., perinuclear accumulation was observed in over
80% of cells and persisted for over 6 hr, suggesting
retention of viral particles at this perinuclear site
(arrows in Fig. 1A). To specifically investigate the
role of the perinuclear retention, we focused on
the time period between 6 and 8 hr after pulse in-
fection, a time point at which, in majority of cells,
most virions have finished cytoplasmic trafficking
and remain at the perinuclear region.
Previous studies have co-localized perinuclear
rAAV particles to the Golgi apparatus,36,37 and
others have suggested that these virions may co-
localize with MTOC.38 As the perinuclear region is
highly crowded and the resolution of classical
fluorescent microscopy is only about 0.3lm in lat-
eral, images solely generated by such fluorescent
microscopy alone could falsely co-localize viral
particles with many cellular organelles at peri-
nuclear region, namely, Golgi, MTOC, and ER.38
To effectively discern which cellular structures at
the perinuclear region co-localize with AAV parti-
cles and retain these virions, we used fluorescence
microscopy and pharmacological interventions
(Fig. 1B) to circumvent the above resolution limit
issues. Specifically, if rAAV particles do co-localize
to and are retained by a particular structure at the
perinuclear region, we shall be able to predict that
(1) the viral accumulation will be ablated upon the
disruption of that structure by pharmacological
agents, and (2) the majority of virions will still co-
localize with that structure after release from the
perinuclear region upon disruption of MTs and
MTOC.
Using several antibodies, we demonstrated that
rAAV particles can be co-stained with markers for
Golgi apparatus and MT-MTOC (peri-MTOC MTs)
at the perinuclear region (Fig. 1C). To distinguish
whether virus localized to the Golgi or MT-MTOC,
we used a panel of pharmacological reagents to
disrupt these structures individually and visual-
ized the localization of viral particles in each case.
Upon Brefeldin-A treatment to specifically dis-
rupt Golgi apparatus, perinuclear accumulation of
AAV was not dispersed (Fig. 1D). In contrast, when
MT-MTOC was fully disrupted by nocodazole, the
perinuclear localization of AAV was ablated and
few rAAV particles co-localized with dispersed
Golgi cisternae (Fig. 1E). Although nocodazole
treatment affects the Golgi apparatus as well,
Figure 1. Perinuclear retention of rAAV by MT-MTOC. Hela cells were fixed to examine the distribution of Cy5-labeled viral particles at various time points after
pulse infection. Nuclei were stained with DAPI (blue). (A) Representative images showing the distribution of intracellular rAAV2 over 12hr after viral inoculation.
Arrows indicate perinuclear accumulation in the cells. (B) Schematic diagram showing the procedure used for drug intervention and confocal imaging
experiments. (C–E) Confocal images showing the localization of MT-MTOC, Golgi apparatus, and rAAV2 when cells were treated with DMSO (C), 2lg/ml
Brefeldin-A (D), and 30lM nocodazole (E). MTs were stained with a-tubulin antibody (green) and Golgi apparatus was stained with Giatin antibody (cyan). Arrows
indicate the perinuclear accumulation of rAAV. The right most panels in (C–E) display schematic cartoons showing the localization of rAAV particles, Golgi, and
MTs in the cells. DAPI, 4¢,6-diamidino-2-phenylindole; rAAV, recombinant adeno-associated virus; MT-MTOC, microtubules at microtubule-organization center.
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based on the result from treatment of Brefeldin A
and nocodazole, these data suggest that rAAV is co-
localized to and retained by MT-MTOC but not
Golgi apparatus at the perinuclear region. This
finding is consistent with previous studies that
show that many other viruses traffic and localize to
MTOC or MT-MTOC.10,14,39,40
Disruption of MT-MTOC retention
increases AAV transduction
To study whether the retention of AAV in MTOC
affects rAAV transduction, we also used anti-MT
drugs (nocodazol, colchicine, rhizoxin, and may-
tansine) to disrupt MTs as described in Fig. 2A. We
infected 293 cells with AAV vector encoding GFP
transgene. Eight hours later, drugs were added to
the cells for 4 hr and washed out. The cells with
GFP expression were analyzed by flow cytome-
try at 20 hr after nocodazole treatment (Fig. 2A).
To exclude potential effects of the reagents on
the second strand synthesis of viral DNA, self-
complementary rAAV (rAAV2-CMV-GFPsc) was
used in the transduction assay.
Disruption of MTs by nocodazole treatment in-
duced a 2–4-fold increase in viral transduction in
multiple cell lines as measured by the expression of
the transgene GFP (Fig. 2B). To rule out the pos-
sibility that the increased viral transduction was
specific to nocodazole, a panel of anti-MT drugs
(AMDs) was used (colchicine, rhizoxin, maytansine),
all of which disrupt MTs. Similar increases in GFP
expression were observed with all of the drugs
(Fig. 2C). We also tested whether stabilization
of MT-MTOC by taxol would reverse the effect of
nocodazole, by comparing the viral transduction in
cells treated with nocodazole alone or with nocoda-
zole and taxol. We found that co-administration of
taxol with nocodazole restored the enhanced viral
transduction to the control level (Fig. 2D). Together,
these results demonstrated that MT-MTOC dis-
ruption is able to increase rAAV transduction.
Increased transduction upon MT-MTOC
disruption is independent of promoter
activity, cell cycle arrest, and viral degradation
Next, we explored the underlying mechanism
associated with the increase in viral transduction
induced by MT-MTOC disruption. We envisioned
three possible mechanisms for the increase in
transgene expression: (1) MT-MTOC disruption
leads to the activation of the promoter on the vi-
ral transgene cassette; (2) MT-MTOC disruption
results in cell cycle arrest that, in turn, leads to
increased viral transduction; (3) MT-MTOC dis-
ruption affects intracellular viral processing or
trafficking. First, we employed in vitro plasmid
transfection to examine the potential effect of MT-
MTOC disruption on promoter activity. Our flow
cytometry data demonstrated that MT-MTOC dis-
ruption by AMDs did not affect the reporter gene
(GFP) expression from the viral transgene cas-
sette, which was directly transfected into the cells
using PEI (Fig. 3A). This excludes the possibility
of AMD treatment affecting promoter activity
(mechanism 1). To test the second possible mech-
anism, we measured the effects of AMD treatment
on viral transduction in cells whose cell cycle was
already arrested at S-phase by double thymidine
block, a step preceding the M-phase block caused
by AMDs. Our data showed that MT-MTOC dis-
ruption also induced an enhancement of viral
transduction in these prearrested cells, suggesting
Figure 2. Disruption of MT-MTOC increases rAAV transduction. (A) Schematic diagram showing the procedure used for the experiments. (B) A variety of cell
lines used to measure rAAV2 transduction with and without nocodazole treatment. MFI of GFP expression is normalized to the DMSO treatments. (C) rAAV2
transduction was determined by MFI of GFP expression in Hela cells treated with various AMDs. (D) The MFI of GFP expression was measured in cells treated
with DMSO, nocodazole, nocodazole+taxol, or taxol only. *Statistically significant difference with p < 0.01. AMDs, anti-MT drugs; MFI, mean fluorescence
intensity.
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that the increase in viral transduction was inde-
pendent of cell cycle arrest induced by disruption of
MT-MTOC (mechanism 2; Fig. 3B). Additionally, it
was previously reported that intracellular degra-
dation of rAAV limits viral transduction and its
blockage using proteasome inhibitors resulted in
dramatic increase in viral transduction.41 It was
also previously proposed that MT-MTOC facili-
tates the degradation of intracellular proteins by
transporting these proteins to and retaining pro-
teasome machineries at the perinuclear region. As
a result, we tested if MT-MTOC disruption has
reduced the rAAV degradation. Data from quanti-
tative PCR demonstrate that the amount of rAAV
measured as genome copy number (vgs/cell) was
not significantly changed upon MT-MTOC disrup-
tion, suggesting that AMD treatment did not affect
the viral degradation (Fig. 3C). This notion was
further supported by our data from pharmaco-
logical intervention studies that showed that
proteasome inhibitor can further enhance viral
transduction if co-administrated with AMDs (Fig. 3D).
Therefore, we have excluded the hypotheses
(1) that MT-MTOC disruption directly increases
transgene expression, (2) that MT-MTOC disrup-
tion acts to increase transduction through cell cycle
arrest, and (3) that MT-MTOC disruption in-
creases rAAV transduction by decreasing the deg-
radation of rAAV virions.
Interestingly, previous studies, including ours,
demonstrated that disruption of MTs during rAAV
entry has a negative effect on transduction because
of impaired cytoplasmic trafficking.30 The data
from previous study and our current findings sug-
gest that (1) MTs are not required for later steps of
transduction after rAAV trafficking to perinuclear
region because MT disruption did not inhibit rAAV
transduction after that time, and (2) though MTs
play a central role in trafficking of the virus to the
perinuclear region, at later time points these
structures act to retain virions and thus limit
transduction. It is unclear how rAAV accumulates
at MTOC and whether any motors are involved in
the process; further studies are warranted.
Nuclear entry of rAAV is increased
upon the disruption of MT-MTOC
Based on the above findings, the most likely
mechanism for elevated viral transduction upon
MT-MTOC disruption occurs at the level of traf-
ficking. It has been previously demonstrated that
nuclear entry is an essential trafficking event for
rAAV’s infectious pathway.42,43 Moreover, nuclear
entry is the most probable event subsequent to and
being limited by perinuclear retention in rAAV’s
infectious trafficking pathway. We hypothesized
that the retention of viral particles at the MTOC
region may limit the subsequent nuclear traffick-
ing of the virus. To test this hypothesis, we visu-
alized viral trafficking steps with and without
Nocodozole treatment by fluorescent confocal mi-
croscopy and quantitatively evaluated the distri-
bution of viral particles at different time points
after administration of nocodazole at 6–8 hr p.i.
(Fig. 4A). At about 1–1.5 hr after MT-MTOC dis-
ruption (*8–9 hr p.i.), the perinuclear retention of
rAAV particles was ablated in most cells examined
(Fig. 4C) and the viral particles spread around the
outside of nucleus (Fig. 4B). Later, *3–4 hr after
MT-MTOC disruption (*10–11 hr p.i.), an approx-
imate 2-fold increase of viral particles was observed
in the nucleus as shown by the representative im-
ages from confocal microscopy (Fig. 4B, C) and
quantitative data from 3D microscopy (Fig. 4B-f/i/l,
and 4D). Increased viral entry into the nucleus was
also supported by quantitative PCR analysis of the
viral genome copy number in the nuclear fractions
of treated and untreated cells (Fig. 4E). Together,
these results suggest that disruption of MT-MTOC
at 6–8 hr p.i. leads to an increase in the fraction of
viruses in nuclear proximity and may explain the
increased transduction we have observed (Fig. 2).
Figure 3. MT-MTOC disruption does not affect promoter activity and viral
degradation. (A) At 16–20 hr after transfection with plasmid TR-CMV-GFP
using polyethyleneimine (PEI), Hela cells were treated with drugs for 3 hr. At
approximately 20 hr after drug treatments, cells were harvested for flow
cytometry analysis to measure the GFP expression. (B) Cell cycle of cells was
arrested using a double-thymidine block and MT-MTOC was disrupted as in
Fig. 2A and rAAV transduction was then measured. (C) Cells were treated as
in Fig. 1B, and quantitative PCR (qPCR) was used to determine the copy
number of the viral genome. (D) Cells were treated as in Fig. 2A except that
proteasome inhibitors were added with AMD at the same time after infection
and transduction was measured. *Statistically significant difference between
DMSO and nocodazole treatments with p< 0.01. AMD, anti-MT drugs.
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Figure 4. Release of rAAV and increased nuclear entry upon MT-MTOC disruption. (A) Schematic diagram showing the procedure for the experiments in
(B–E). Specifically, Hela cells were treated with DMSO or nocodazole at 6–8 hr after pulse infection of Cy5-rAAV2 and fixed at 1–1.5 hr or 3–4 hr after drug
treatments. Nuclei were stained with DAPI (blue). (B) Representative images from 2D confocal microscopy of one focal plane (a–c) and 3D images
reconstructed from confocal Z-stacks as described in Materials and Methods. (d–l) Viral distribution in cells treated with DMSO (a, d, g, j) or with nocodazole
for 1–1.5 hr (b, e, h, k) or 3–4 hr (c, f, i, l). (d–f) are top views, whereas (g–i) are magnified side views from directions indicated by arrows in (d–f),
respectively. (j–l) are views observed inside the nucleus (from the directions indicated by arrows in (g–i), respectively, between the top and bottom nuclear
envelopes, which is indicated by the blue layer based on the DAPI signal). rAAV2 particles in cytoplasm are highlighted in red and those inside the nucleus
highlighted in yellow. (C) The proportion of cells with perinuclear accumulation of rAAV particles after DMSO or nocodazole treatment (for 1.5 or 3 hr) was
quantified in 50–100 cells for each group. The perinuclear accumulation is defined as concentrated viral particles at a single perinuclear region (arrows in Fig. 2
and arrowheads in Fig. 5B). (D) The proportion of rAAV particles entering nucleus in cells treated with DMSO or nocodazole at 3 hr was quantified from the 3D
microscopy data (Fig. 5B). From each group, 20–30 cells were used for the 3D quantitative microscopy described in Materials and Methods. (E) Nuclei were
fractioned from cells and qPCR was used to determine the copy number of rAAV genomes in the nucleus of cells treated with nocodazole for 3 hr, in
comparison with DMSO-treated cells. (F) Cells were treated with DMSO or nocodazole as described in Fig. 1A and then transduced with AAV or BR mutants of
AAV, and transduction was analyzed by flow cytometry. GFP expression is normalized to that in DMSO-treated group. *Statistically significant difference
between DMSO and nocodazole treatments with p< 0.01.
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Three major basic regions (BRs) on the capsid
have been shown to function as nuclear localization
signals (NLS) with varying strength.42,43 rAAV
mutants with deletions at these regions can still
accumulate at the perinuclear region but are un-
able to enter nucleus.37 Our prior study has dem-
onstrated that pronounced Golgi localization is
observed with the BR1 mutant, and the BR2 and
BR3 capsid mutants appear to have diffuse locali-
zation throughout the cell in addition to localizing
to the Golgi.37 To test whether NLS are required for
the increased nuclear entry and viral transduction,
we examined the effects of MT-MTOC disruption
on these BR deletion mutants. In both DMSO- and
nocodazole -treated cells, BR deletions resulted in
the reduced viral transduction (Fig. 4F). Im-
portantly, nocodazole treatment was unable to
restore the impaired transduction of these BR
mutants, indicating that AMD-induced enhance-
ment of viral transduction and nuclear entry re-
quires the capsid NLSs. These data suggest that
MT-MTOC disruption releases rAAV to continue
down its normal nuclear entry pathway and does
not cause rAAV’s nuclear entry pathway to change.
rAAV is imported into the nucleus
via the RhoA-ROCK-Actin pathway
upon MT-MTOC disruption
The above findings suggested that MT-MTOC
disruption itself allows only the release of rAAV
particles from the perinuclear region. The subse-
quent increase in nuclear entry is achieved by a
mechanism that requires the NLS on viral capsid.
It is well established that MT disruption can lead to
RhoA-ROCK mediated rearrangement of actin fil-
aments (AFs), which in turn may affect actin-
mediated intracellular trafficking.44,45 Perinuclear
AFs have been suggested to be involved in nuclear
import/export of intracellular materials via as-
sociation with the nuclear envelope or perhaps
nuclear pore complexes.10,46–55 In this study, we
tested whether the AFs regulated by the activation
of RhoA-ROCK upon MT disruption contributed to
the increased rAAV nuclear entry and transduc-
tion. First, we transiently transfected siRNA to
knockdown the expression of endogenous RhoA as
demonstrated by immunoblotting for the RhoA
protein (Fig. 5A). Interestingly, treatment with
nocodazole induced an increase in viral transduc-
tion only in cells transfected with the control
(scrambled) siRNA and had minimal effect in RhoA
knockdown cells (Fig. 5B). This observation sug-
gests that enhanced AAV transduction via MTOC
disruption requires RhoA activation. H1152 is a
potent inhibitor of ROCK, a downstream effector of
RhoA, and induces actin filament alterations. Cy-
tochalasin D (CytoD) is an inhibitor of AFs that
induces the de-polymerization of these filaments.56
Both H1152 and CytoD were found to ablate the
transduction enhancement induced by MT-MTOC
disruption with nocodazole; therefore, the en-
hancement of transduction required that ROCK
not be inhibited and that AFs be intact (Fig. 5C).
The data suggest that the RhoA-ROCK-Actin
pathway is required for the increased viral trans-
duction upon MT-MTOC disruption. Visualization
of viral particles by fluorescence microscopy re-
vealed that nocodazole -induced viral dispersion
from the perinuclear region was unaffected by co-
administration with H1152 or CytoD (Fig. 5D). Our
results from 3D quantitative microscopy fur-
ther demonstrated that co-administration of ei-
ther H1152 or CytoD blocked the increase in viral
nuclear entry only after MT-MTOC disruption
(Fig. 5E). Additionally, administration of H1152 or
CytoD alone at 6–8 hr p.i. did not affect the trans-
duction and nuclear entry of rAAV (Fig. 5C, E).
Together, the above data suggest a two-step
working mechanism for the increased rAAV trans-
duction observed upon MT-MTOC disruption: (1)
viral particles are released from the perinuclear
region and spread around the outside of the nu-
cleus upon MT-MTOC disruption, and (2) some of
these viral particles are then transported into the
nucleus via the RhoA-ROCK-Actin pathway.
Perinuclear retention of rAAV and
nocodazole-mediated enhancement
on viral transduction also occur in vivo
In cell culture, we observed a bottleneck in viral
transduction at the stage of accumulation and re-
tention of rAAV at MTOC region. rAAV is currently
widely used as a gene therapy vector in many
clinical trials to tackle a variety of human dis-
eases.27 The effort to improve its efficiency in gene
delivery has been compromised by the lack of
knowledge about rAAV trafficking in in vivo set-
tings. With the sensitive imaging technique used in
this study, we examined whether perinuclear re-
tention of rAAV also acted as a bottleneck in vivo.
To examine this hypothesis, we injected Cy5-rAAV
into mouse brain, liver, or xenografted tumor,
and determined the viral distribution at different
time points after viral infection. At an early stage
(*1 hr) after viral inoculation, viral particles were
scattered across cells in these tissues, as is clearly
observed in the brain image (Fig. 6A). Because of
the relatively high background fluorescence ob-
served in both liver and xenografted tumor, we
were not able to visualize single viral particles in
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these tissues as observed in the brain; instead, we
were able to visualize particles only at the sites
of viral injection, where a higher concentration
of labeled virions was present (arrowheads in
Fig. 6A). At 6–12 hr p.i., a large number of viral
particles were observed to accumulate at the peri-
nuclear region, consistent with our in vitro studies
(Fig. 6A). Approximately 60–80% of cells in these
tissues had perinuclear accumulation by 12 hr after
infection (arrows in Fig. 6A, B).
Furthermore, we tested whether AMD treat-
ment could disrupt this perinuclear retention and
increase viral transduction in mouse as was ob-
served in our in vitro studies. Approximately 10 hr
after viral inoculation, nocodazole was adminis-
trated to the animal through intraperitoneal or
intratumoral injection. At 4–6 hr after nocodazole
injection (*14–16 hr p.i.), perinuclear retention
(arrows in Fig. 7A) was observed only in DMSO-
treated animals and was ablated in the cells of both
liver and xenografted breast tumor in nocodazole -
treated animals (Fig. 7A). Using GFP as a reporter
gene packaged by rAAV, a significantly stronger GFP
fluorescent signal was observed in the nocodazole-
treated breast tumors (Fig. 7B). Moreover, by mea-
suring luciferase activity using the IVIS imaging
system, we observed a roughly 10-fold increase of
viral transduction in both liver and xenografted tu-
mor of nocodazole-treated mice (Fig. 7C, D). To-
gether, these data suggest that rAAV takes a similar
subcellular trafficking route in animal tissues to that
in vitro and is retained at the perinuclear region, a
trafficking bottleneck for viral transduction.
DISCUSSION
Viral accumulation at the perinuclear region
is commonly observed during the infection of
many viruses (e.g., Ad, HSV, HIV, influenza,
parvoviruses).11,13–15,39 However, it remains un-
clear regarding whether and how this accumulation
affects viral infection. Two plausible hypotheses9 are
(1) viruses exploit the cellular protein-trafficking
machineries to approach the replication site or to
concentrate viral components for viral replication
and later virion assembly, thus supporting viral in-
fection, and (2) perinuclear accumulation represents
an innate cellular response that recognizes virus
Figure 5. Disruption of MT-MTOC increases viral transduction and nuclear entry through an RhoA-ROCK-Actin pathway. (A) Immunoblot showing the siRNA-
mediated transient knockdown of the RhoA protein in Hela cells. Scramble siRNA used as a control. (B) The level of rAAV transduction was measured in
Scramble or RhoA siRNA-transfected cells treated with or without nocodazole treatment at 6–8 hr after rAAV infection. (C) The level of rAAV transduction was
determined in cells treated with DMSO or nocodazole alone or in combination with H1152 or CytoD. (D) The proportion of cells with perinuclear accumulation
of rAAV particles was measured in the presence of DMSO or nocodazole alone or in combination with H1152 or CytoD. (E) The proportion of rAAV particles in
the nucleus was determined in cells treated with DMSO or nocodazole alone or in combination with H1152 or CytoD. *Statistically significant difference
between DMSO only and other drug treatments with p < 0.01.
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components as foreign or misfolded proteins and
targets them for sequestration and degradation at
the perinuclear region, thus interfering with viral
infection. Our present study has supported the hy-
pothesis that perinuclear accumulation is a cellular
defense mechanism to sequester virions in order to
limit the infection of rAAV.
Both Golgi and MTOC are perinuclear structures
that coincidentally co-localize at the perinuclear
region with many viruses.10,11,13–16 However, it
Figure 7. Disruption of perinuclear accumulation of rAAV particles with nocodazole treatment increases transduction in vivo. (A) Representative images
showing the distribution of rAAV particles (red) in tissues treated with DMSO or nocodazole. Nuclei are stained with DAPI (blue). Arrows indicate the
perinuclear accumulation of virions. (B) Representative images showing the viral injection sites as visualized with injected India ink (arrows on the upper
panel) and transgene GFP expression (green in lower panel) in the xenografted tumors. (C) IVIS imaging of luciferase signal in xenografted breast tumor and
liver at 1 week after viral injection. Left panel shows the luciferase activity in the xenografted tumor before (upper image) or after (lower image) removal from
the mice. Right panel shows the luciferase activity from liver expression. (D) The relative luciferase activity in the tumor and liver was quantitated as photons/
sec/cm2 (n= 3–4). *Statistically significant difference between DMSO and nocodazole treatments with p< 0.01.
Figure 6. Perinuclear accumulation of rAAV in mouse tissues. Mouse tissues (brain [cerebrum], liver, xenografted breast tumor) were removed at 1 or 12 hr
after injection of Cy5-rAAV and sectioned using a cryo-microtome. Nuclei are stained with DAPI (blue). The viral particles were visualized by confocal
microscopy. (A) Representative confocal images showing the viral distribution in uninfected mouse tissues (control) or tissues that were infected with rAAV
for 1 or 12 hr. Arrowheads indicate concentrated rAAV at the injection site. Arrows indicate perinuclear accumulation of virions. (B) The percentage of cells
with perinuclear accumulation of rAAV in each tissue was measured at 1 hr postinfection (p.i.) and 12 hr p.i. For each group 50–100 cells were analyzed.
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remained unclear which cellular structure main-
tains perinuclear accumulation of rAAV. Earlier
studies have suggested that the perinuclear viral
particles co-localize to the Golgi apparatus.36,37 An-
other study suggests that these virions may co-
localize with MTOC.38 In this study, to examine
which structure was involved, we used confocal
fluorescence microscopy and pharmacological inter-
vention to circumvent the difficulties in studying the
interactions between virions and cellular structures
at the highly crowded perinuclear region because of
the resolution limits of classical fluorescence mi-
croscopy (*0.3lm in lateral). Our results suggest
that MT-MTOC but not the Golgi co-localizes with
and retains the rAAV particles at perinuclear region
(Fig. 1). Consistent with our findings, many other
viruses, including Ad, HSV, and HIV, have also been
shown to move on MTs to the MTOC region and
associated with MT-MTOC.10,14,39,40,57–62 Further-
more, Fig. 1E shows that only a small portion of viral
particles co-localized with the dispersed Golgi cis-
ternae, which are released from highly packed
MTOC region upon MT-MTOC disruption. This
suggests that fewer particles physically localize in
the Golgi apparatus. Consistent with previous re-
ports, we did find that disruption of the Golgi ap-
paratus at an earlier time during infection could
impair rAAV transduction (data not shown). These
data indicate that the Golgi does play a role in viral
infection, probably through modification of viral
capsid critical for viral infection, but is dispensable
for perinuclear retention of incoming virions. Fur-
ther investigation of the exact role of the Golgi ap-
paratus on the infection of rAAV may advance our
current knowledge of virology.
Our results, together with previous studies,
strongly suggest that perinuclear retention by
MTOC during early infection serves as a cellular
barrier limiting viral transportation to the repli-
cation sites and leads to decreased viral transduc-
tion. During early infection stage, in which a virus
delivers its genome to the target site for replication,
accumulation of incoming virions at MTOC region
is observed for most viruses that exploit MTs for
earlier cytoplasmic trafficking.10–15,39 Consistent
to these findings, we demonstrated that retention
of rAAV by MT-MTOC limits viral transduction,
and that disruption of MT-MTOC during infection
led to an increase in rAAV transduction (Fig. 2E).
Strikingly, some viruses may have evolved to
overcome the MTOC retention by breaking MTs
during their infection.18–22 For instance, HSV dis-
mantle MT-MTOC after entering the cells as one of
the functions of viral protein ICP0 and deletion of
ICP0 seems to limit viral infection.21
Our current study raises an interesting question
for future exploration, which is whether and how
the endosomal vesicles at MTOC region may con-
tribute to the rAAV transduction enhancement
observed upon MT-MTOC disruption. A reasonable
hypothesis is that at 6–8 hr p.i., some viral particles
observed at the MTOC region still remain inside
the MT-localized endosomes/lysosomes,32,63 whereas
others have escaped the endosomes and directly
associated with MTs. Direct interaction between
MTs and the rAAV capsid has been demonstrated
previously.64 Both endosomal and escaped viral
particles would be released from the MTOC region
upon MT-MTOC disruption. Using rAAV mutants
with defects in the phospholipase (PLA) domain
that helps rAAV for endosome escape,37 we deter-
mined that MT-MTOC disruption was unable to
rescue the impaired viral transduction of these
mutants (data not shown), which suggests that
MT-MTOC disruption does not promote the escape
of rAAV from endosomes. Further experiments
should be performed to test whether nocodazole-
mediated RhoA activation is not involved in endo-
some escape in the MTOC region with PLA mutant.
Furthermore, increased viral particles reaching
the nucleus upon disruption of MT-MTOC are most
likely the subset of virions that have escaped from
endosomes and are directly associated with MTs.
Those virions that failed to escape endosomes are
not eligible for nuclear entry regardless of the in-
tegrity of MT-MTOC. This notion is consistent with
our observation that the proportion of nuclear
particles increases from only about 30% to 50%,
possibly because about 30–40% of virions are still
inside the endo/lysosomes at 8 hr p.i.32 In the fu-
ture, it will be interesting to investigate the po-
tential role of endo/lysosomal vesicles on viral
retention at the perinuclear region, which would
add valuable information to the mechanism of this
perinuclear phenomenon. Additionally, the rela-
tionship of free rAAV particles in the cytoplasma
with MT should be elucidated.
Actin filaments (AFs) and small Rho GTPases
have been shown to be involved in viral infection,
including cell entry, cytoplasmic trafficking, and
nuclear entry.36,56,65–67 Recently, perinuclear and
nuclear AFs were shown to associate with the nu-
clear envelope and nuclear pore complex, and were
suggested to be involved in nuclear transport of
macromolecules and viral particles.46–50,66 rAAV
has been suggested to utilize AFs to enter nucleus
during an earlier stage of infection when MTs were
disrupted.30 Furthermore, the disruption of MTs
leads to a RhoA-ROCK-mediated rearrangement of
AFs.44,45 Consistent with these studies, our data
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show that AFs may facilitate the increase in
nuclear entry through the RhoA-ROCK pathway
upon MT-MTOC disruption (Fig. 5). Interruption
of this pathway in the presence of intact MTs does
not affect the level of viral transduction. This
finding indicates that, at this time point, nuclear
import of rAAV by AFs occurs only upon the dis-
ruption of MT-MTOC. It is possible that the AAV
capsid has a much higher binding affinity for
MTs than for AFs, and therefore remains associ-
ated with MT-MTOC. Moreover, the requirement
of RhoA and ROCK activity indicates that MT
disruption-induced alterations of AFs are neces-
sary for the increase in viral nuclear entry and
transduction. One possibility is that activated
RhoA-ROCK results in more AFs connecting to the
nuclear pore complex, which in turn transports
more rAAV particles into the nucleus. Further
study of this mechanism will add more detail to
current knowledge of viral nuclear entry as well as
the biology of cellular cytoskeletons.
Although tremendous progress has been made in
understanding the trafficking of rAAV virions in
cell culture, little is known about the trafficking
pattern of this virus in vivo. This has limited one’s
ability to improve the efficiency of viral transduc-
tion for gene delivery in its natural environment.
In this study, we examined the trafficking of rAAV
in mouse tissues, including brain, liver, and xeno-
grafted tumors. In each of these tissues, the viral
particles accumulate at a perinuclear site, resem-
bling our in vitro observations (Fig. 6). Treatment
with nocodazole was able to disrupt the perinuclear
retention of rAAV and increase the viral trans-
duction in all tissues tested (Fig. 7). Although fur-
ther investigations are needed to refine the details
of viral trafficking in these tissues, to our best
knowledge, this is the first study to verify an
in vitro trafficking pathway in in vivo settings.
Additionally, the data showing that nocodazole
treatment can enhance rAAV transduction in
breast cancer cells indicate that there may be
a synergistic effect between chemotherapeutic
drugs, such as AMDs, and rAAV-mediated gene
therapy in treating cancer patients. In this study,
we studied the enhancement effect of MT-MTOC
disruption after virus entry on rAAV2 transduc-
tion. Since different serotypes of AAV may use
different mechanism for intracellular trafficking, it
should be warranted whether the MT disruption
also has an enhanced effect on transduction from
other serotypes of AAV after cell entry.
In summary, our current study examined the
mechanism of perinuclear retention of the parvo-
virus AAV and the corresponding effects on viral
infection. Our data demonstrated that perinuclear
retention by MT-MTOC serves as a subcellular
barrier and limits rAAV infection, specifically at
the step of nuclear entry, providing a novel host
defense mechanism to sequester incoming virions.
These studies may shed light on mechanisms of
viral pathogenesis, especially under circumstances
of MT disassembly during cell division and that of
MTOC malfunction caused by misfolded-protein
diseases or treatment with chemotherapy drugs.
Moreover, further understanding of the determi-
nants on the virus responsible for perinuclear re-
tention may also lead to novel strategies for the
enhancement of rAAV vector for gene delivery.
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